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High blood pressure in older subjects with cognitive impairment
L'ipertensione arteriosa nell'anziano con deficit cognitivo
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Abstract
High blood pressure and cognitive impairment often coexist in old
age, but their pathophysiological association is complex. Several longi-
tudinal studies have shown that high blood pressure at midlife is a risk
factor for cognitive impairment and dementia, although this associa-
tion is much less clear in old age. The effect of blood pressure lowering
in reducing the risk of dementia is only borderline significant in clin-
ical trials of older subjects, partly due to the insufficient follow-up time.
Conversely, dementia onset is associated with a decrease of blood pres-
sure values, probably secondary to neurodegeneration. Prognostic ef-
fect of blood pressure values in cognitively impaired older subjects is
still unclear, with aggressive blood pressure lowering being potentially
harmful in this patients category.
Brief cognitive screening, coupled with simple motor assessment, is
warranted to identify frail older subjects who need a more cautious ap-
proach to antihypertensive treatment. Values obtained with ambulatory
blood pressure monitoring seem more useful than clinical ones to pre-
dict the outcome of cognitively impaired older subjects. Future studies
should identify the most appropriate blood pressure targets in older
subjects with cognitive impairment. 
Riassunto 
Ipertensione arteriosa e decadimento cognitivo spesso coesistono in
età avanzata, sebbene la loro associazione sia complessa dal punto di
vista fisiopatologico. Diversi studi longitudinali hanno mostrato che
elevati valori pressori in età adulta rappresentano un fattore di rischio
per decadimento cognitivo e demenza, sebbene tale associazione sia
molto meno chiara in età avanzata. L’effetto della terapia antiiperten-
siva è risultato ai limiti della significatività statistica nel ridurre il ri-
schio di demenza negli studi di intervento su soggetti anziani, in parte
a causa della durata insufficiente del follow-up. D’altra parte, l’insor-
genza di demenza è associata con una riduzione dei valori pressori,
probabilmente secondaria alla neurodegenerazione. L’effetto progno-
stico dei valori pressori in anziani con decadimento cognitivo non è
stato ancora chiarito, in presenza di un possibile effetto dannoso di un
trattamento antiipertensivo aggressivo in questa categoria di pazienti.
Un breve screening cognitivo, associato con una semplice valutazione
motoria, è raccomandato per identificare gli anziani fragili, che neces-
sitano di un approccio più cauto alla terapia antiipertensiva. I risultati
del monitoraggio della pressione arteriosa nelle 24 ore sembrano più
utili della misurazione clinica per predire la prognosi degli anziani co-
gnitivamente compromessi. Studi futuri dovrebbero identificare gli
obiettivi pressori più appropriati nel trattamento di anziani con deca-
dimento cognitivo.
Introduction
The importance of blood pressure and cognitive impairment in old
age is highlighted by several reasons. The main reason is that high
blood pressure (HBP) and different forms of cognitive impairment are
highly prevalent and often associated in old age. According to available
data, 54% of older males and 57% of older females have HBP[1]. De-
mentia affects 6-8% of subjects aged 60+ years and as much as 25% of
those aged 85+[2], whereas mild cognitive impairment (MCI), a less
severe form of cognitive decline that may herald the development of
overt dementia, is observed in a large proportion of subjects over 65,
with prevalence estimates of about 25% [3]. 
HBP often coexists with cognitive impairment in old age, consis-
tently with data which have identified it as a risk factor for cognitive
impairment and dementia[4]. This has been shown clearly for vascular
dementia, which is characterized by macro- and/or microvascular le-
sions, whose main risk factor is represented by HBP [5]. Yet the patho-
physiological association between blood pressure and cognition during
life-course is complex and varies in strength and direction with time,
as discussed below. Most importantly, subjects in advanced age have
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sociated with a greater risk of subsequent cognitive decline in the 65-
74 cohort, BP seemed to have a neutral effect between 75 and 84, and
the opposite association was observed in subjects aged 85 [14].
Moreover, in Leiden 85-Plus study an analysis stratified for baseline
disability was performed, showing a much greater association between
lower systolic BP values and subsequent cognitive impairment in sub-
jects with ongoing disability status [15].
An analysis from the National Health and Nutrition Examination
Survey (NHANES) supports a role for motor performance as a powerful
modulator of BP associated mortality risk, irrespectively of cognitive
impairment. In fact, in a cohort of 2340 older subjects (mean age 74),
the association between BP and 7-year mortality varied markedly
among subjects, according to their ability to walk 6 m as fast walkers
(≥0.8 m/sec), slow walkers (<0.8 m/sec) or unable to complete the task.
In fact, while high SBP was associated with increased mortality among
fast walkers, the association disappeared among slow walkers and was
reverted among subjects unable to walk, who had a greater risk associ-
ated with low values of SBP and DBP [16].
Therefore, available evidence supports the hypotheses that advanced
age per se and/or functional impairment might affect the association
between blood pressure values and prognosis.
The effect of dementia on BP values: 
reverse causation
While the prognostic role of high BP in regard to dementia in old age
is debated, several studies have shown an effect of dementia onset in
reducing BP values. Therefore, in life-course studies, high BP values
have been associated with increased dementia risk after decades,
while cognitive impairment is followed by BP values decline [17]. As
dementia severity and brain atrophy are correlated with low BP values
over 85, this phenomenon is thought to be secondary to neurodegener-
ation [18]. Therefore, a window of opportunity is depicted, during
which AHD have the potential to decrease dementia risk; conversely de-
mentia onset represents a risk factor of hypotension, calling for de-in-
tensification of treatment to reduce the risk of adverse events.
AHD in subjects with ongoing cognitive
impairment/dementia: risks and benefits
Subjects with cognitive impairment represent a subpopulation at
high risk for cerebrovascular damage and brain hypoperfusion, making
the effect of AHD on cognitive function difficult to foresee. In fact data
are not clear-cut. One study of 1385 subjects with mild cognitive im-
pairment (mean age 73.6, baseline MMSE 28/30), has found a faster
progression of cognitive decline over 2 years among subjects with re-
peated detection of high BP (≥140/90 mmHg) [19]. In keeping with
these data, subjects with mild cognitive impairment (mean age 67.8,
baseline MMSE 26/30) have been found to have an increased risk of
conversion to Alzheimer’s disease after five years, while AHD reduced
the risk [20]. Moreover, in subjects with Alzheimer’s disease an asso-
ciation between higher SBP values and greater cognitive decline was
observed in one study [21], but not in another [22]. A recent study con-
ducted with ambulatory blood pressure monitoring (ABPM) in a sample
of 172 older subjects with dementia or mild cognitive impairment
(mean age 79, MMSE 22/30) has observed an increased risk of cogni-
tive decline after 9 months among subjects with lower mean daytime
SBP (<129 mmHg) actively treated with AHD [23]. Another recent
study of 141 subjects with mild cognitive impairment (mean age 74)
both highest cardiovascular risk and potentially severe adverse effects
from antihypertensive drugs (AHD) [6]. This is even clearer with re-
gard to the potential role of AHD in preventing cognitive decline, which
is far less established in comparison with other health related out-
comes [7], with some observational data [8] even showing a reverse
association between blood pressure and dementia risk in older subjects
on AHD. Even less is known about the prognostic role of HBP and AHD
when cognitive impairment and dementia are already present.
Available clinical evidence regarding this issue is synthetized
below, and suggestions regarding the role of cognitive assessment in
decisions regarding antihypertensive treatment strategies are given at
the end.
High blood pressure and risk of cognitive
impairment/dementia during the life course
Early cross-sectional studies searching for the association between
BP and cognition have given inconsistent results, as all kind of associ-
ation have been identified in different samples, including positive,
negative, U-shaped, and also no association [4].
Longitudinal studies have made the picture clearer, as the majority,
albeit not the total, of them, have identified an association of HBP
with subsequent cognitive impairment and dementia [4]. This prog-
nostic association was clearly identified for high systolic blood pres-
sure (SBP) at midlife, predicting dementia and Alzheimer’s disease
after a 20-year follow-up time [9]. A similar association was also ob-
served at age 70, with HBP being associated with the risk of both de-
mentia and Alzheimer’s disease 15 years later [10]. Yet more complex
[11] and even reverse association [12] between blood pressure values
and risk of dementia in old age have been observed over the age of 75.
Efficacy of AHD in reducing the risk 
of dementia in old age: evidence based data
None of the randomized controlled trials which have shown the pre-
ventive efficacy of AHD in old age included cognitive impairment or
dementia as primary outcome. This is important for data interpreta-
tion, as the sample size and, most notably, the follow-up time needed
to identify such an effect is likely greater from what is needed from
cardiovascular outcomes. Syst-Eur was the only single study which
have shown the ability of AHD in reducing dementia risk significantly,
and this was observed only in the 4-year open label extension [13].
The meta-analysis of HYVET-Cog together with Syst-Eur, SHEP, and
PROGRESS results have identified a borderline significant 13% rela-
tive risk reduction in AHD arm vs. placebo, thus supporting a potential
preventive role in a context of wide heterogeneity of effects [7].
Modulators of preventive role of AHD 
age and functional status
Due to the inconsistency of results regarding the prognostic role of
BP with regard to cognitive impairment and dementia in old age the
identification of subgroup of subjects with different features seems
clinically relevant.
One of the main modulating factors identified is age, as shown by
the meta-analysis of two Dutch epidemiological studies: the Rotterdam
study, including subjects aged 55-84 and the Leiden 85-Plus study, in-
cluding subjects aged 85 at baseline. While higher SBP values were as-
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has observed an independent association between orthostatic hypoten-
sion and increased risk for conversion to dementia after 2 years [24].
Therefore, the presence of mild cognitive impairment might be a caveat
for possible detrimental effects of excessive blood pressure lowering, at
least among oldest old and for subjects with orthostatic hypotension and
overt dementia. ABPM seems to be more useful than clinical measure in
predicting the cognitive detrimental effects of hypotension.
The role of cognitive assessment in deciding
regarding antihypertensive treatment
Limitations in activities of daily living and cognitive impairment fre-
quently occur during old age. Several longitudinal data have associated
HBP with risk of disability onset [25]. Together with increased stroke
risk, the increased risk of cognitive impairment onset linked with mi-
crovascular cerebral lesions, also without acute cerebrovascular events,
might explain this association [26]. Of notice, the extent of brain mi-
crovascular changes has been associated with extra-cerebral end organ
damages in HBP, including chronic kidney damage [27], increased left
ventricular mass [28] and retinal microvascular changes [29].
Therefore, the assessment of cognitive status in older hypertensives
subjects have two different aims:
1) to have an indirect, easy obtainable estimate of brain end organ
damage associated with high BP;
2) to assess the prognostic role of BP values in the context of the bi-
ological age of the single subject, including the presence of cogni-
tive impairment. 
Several short measures of cognitive status among older subjects
exist and can be used in clinical practice. Among such measures, Mini
Mental State Examination (MMSE) [30] is one of the best known and
probably represents a “gold standard” for brief cognitive assessment,
due to its widespread use both in clinical and in research setting all
over the world, the ability to reliably identify dementia and stage its
severity and the possibility to follow-up patients over time [31]. The ad-
ministration of the test is 5-10 minutes long, depending on patient’s
cognitive status, and includes items testing orientation to space and
time, words repetition and recall, attention and calculation, word
finding, phrase repetition, comprehension of spoken and written lan-
guage, and constructional praxis. The total score is included between 0
and 30, with higher values representing better cognitive function and
24 being the most widely adopted cut-off for dementia. Locally validated
rules exist to adjust the score for age and education. While this instru-
ment will probably be widely adopted in a geriatric facility, it will be
probably felt as too time consuming in a cardiologic setting or in a typ-
ical hypertension clinic. A suitable, less time-consuming alternative for
cognitive screening is the Mini-Cog [32], which requests only a 2-
minute assessment, including the recall of the 3 words, similar to the
MMSE, and the drawing of a clock. The scoring of the test is straight-
forward, as shown in Figure 1. 
To reduce the risk of false positives, it is recommended to corrobo-
rate the suspect of dementia, as resulting from Mini-Cog, with 
1. report of cognitive impairment by patient himself and/or relatives,
in agreement with accepted criteria for dementia and Mild Cogni-
tive Impairment [33];
2. impairment in instrumental activities of daily living, especially
those not requiring preserved physical performance, such as use of
telephone, handling medications and finances, which appears to
be fairly specific for dementia [34].
Since 2013, European [35] and US [36] guidelines have acknowl-
edged different cut-offs and target values for antihypertensive drugs
treatment in old age. Moreover, European guidelines leave to the clin-
ical judgment of the treating physician the choice regarding “frail”
older subjects. In fact, several studies in most recent years have
Figure 1. Mini-Cog Test [32]: administration and scoring
1. Ask the patient to repeat 3 semantically unrelated words
2. Ask the patient to draw a clock
 Draw a circle
 Add the numbers
 Set the time on 11:10
3. Ask the patient to recall the previously repeated words
Clock Drawing Test (CDT) is normal if all numbers are present in the right sequence and position and clock’s hands are in the right position. Test is
scored according to the following algorithm:No
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pointed out at a role for “frailty” in increasing the risk associated with
antihypertensive treatment among elderly subjects [37]. 
In geriatric research frailty is conceptualized as a physiological syn-
drome characterized by decreased functional reserve and diminished
resistance to stressors, causing vulnerability to adverse health out-
comes, including disability and death [38]. While frailty should be re-
liably identified with a comprehensive geriatric assessment, identi-
fying multiple physical, mental and social impairments whose accumu-
lation may ultimately lead to the increased vulnerability status [39],
rapid screener for this condition are often needed In clinical practice
due to time and resource constraints. Therefore simple clinical tools
have been operationalized to detect frailty with sufficient sensitivity
and specificity [40], including instruments based on lower extremity
performance, that seem to be the most useful for this purpose [41].
This seems clinically significant also in the perspective of HBP treat-
ment, in agreement with the above cited data showing an association
between high SBP and increased mortality among fast walkers, no as-
sociation between blood pressure and mortality among slow walkers
and association between low blood pressure and increased mortality
risk among subjects unable to walk [16]. 
Moreover, in keeping with recent data suggesting an association be-
tween low daytime SBP, as measured with ABPM, and greater cognitive
decline among cognitively impaired older subjects treated with AHD
[23], a less aggressive antihypertensive treatment might be warranted
also in this category of patients. Yet, a treatment discontinuation ran-
domized trial of 385 older subjects 75+ with mild cognitive decline
(mean age 81, MMSE 26/30) was recently published. Subjects were in-
cluded if they took at least one antihypertensive drug and SBP was
≤160 mmHg. After 16 weeks SBP went from 148.8 mmHg to 154.2
mmHg, but no positive effect was evident on cognitive function, psy-
chological status or daily functioning [42].
On the whole, the presence of cognitive and motor impairment
might be a useful marker of increased vulnerability to AHD, although
specific cut-off values for different patients categories have to be iden-
tified. Conversely, the recently published SPRINT trial suggests that, in
older patients without severe disability, cognitive impairment, cere-
brovascular disease and diabetes mellitus, lower blood pressure are as-
sociated with better outcomes. These factors suggest that vascular risk
factor prevention, including antihypertensive treatment, should be per-
sonalized in older subjects, and should include the measure of simple
frailty indexes, with a possible referral of the most complex cases to a
comprehensive geriatric assessment [43]. 
Further studies of treatment de-intensification are warranted, with
the aim of identifying the role of different BP measures (clinical vs am-
bulatory) and different BP targets for specific subgroups of frail older
subjects, with a specific focus on cognitive impairment.
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